A systematic review of treatment strategies for erythrodermic psoriasis

References

• Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(4):655–662.
   PubMed Web of Science ®Google Scholar
• Singh RK, Lee KM, Ucmak D, et al. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. PTT. 2016; 6:93–104.
   Web of Science ®Google Scholar
• National Psoriasis Foundation. Erythrodermic psoriasis; [cited 2019 August 18]. Available from: https://www.psoriasis.org/about-psoriasis/types/erythrodermic.
   Google Scholar
• Howick J, Chalmers I, Glasziou P, et al. OCEBM Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine; [cited 2019 Aug 18]. Available from: https://www.cebm.net/index.aspx?o=5653.
   Google Scholar
• Charbit L, Mahé E, Phan A, et al. Systemic treatments in childhood psoriasis: a French multicentre study on 154 children. Br J Dermatol. 2016;174(5):1118–1121.
   PubMed Web of Science ®Google Scholar
• Franchi C, Cainelli G, Frigerio E, Garutti C, et al. Association of cyclosporine and 311 nM UVB in the treatment of moderate to severe forms of psoriasis: a new strategic approach. Int J Immunopathol Pharmacol. 2004;17(3):401–406.
   PubMed Web of Science ®Google Scholar
• Giannotti B, Carli P, Veller Fornasa C, et al. Management of erythrodermic psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Dermatol. 1993;187(1):30.
   Google Scholar
• Kim BS, Shin KS, Youn JI, et al. Treatment of erythrodermic psoriasis with etretinate. Ann Dermatol. 1991;3(2):107–111.
   Google Scholar
• Kokelj F, Plozzer C, Torsello P, et al. Efficacy of cyclosporine plus etretinate in the treatment of erythrodermic psoriasis (three case reports). J Eur Acad Dermatol Venereol. 1998;11(2):177–179.
   PubMed Web of Science ®Google Scholar
• Kumar B, Dhar S, Handa S, et al. Methotrexate in childhood psoriasis. Pediatr Dermatol. 1994;11(3):271–273.
   PubMed Web of Science ®Google Scholar
• Rosińska D, Wolska H, Jablonska S, et al. Etretinate in severe psoriasis of children. Pediatr Dermatol. 1988;5(4):266.
   PubMed Web of Science ®Google Scholar
• Esposito M, Mazzotta A, de Felice C, et al. Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol. 2006;155(1):156–159.
   PubMed Web of Science ®Google Scholar
• Heikkilä H, Ranki A, Cajanus S, et al. Infliximab Combined With Methotrexate as Long-term Treatment for Erythrodermic Psoriasis. Arch Dermatol. 2005;141(12):1607–1610.
   PubMedGoogle Scholar
• Lisby S, Gniadecki R. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis. Acta Derm Venereol. 2004;84(3):247–248.
   PubMed Web of Science ®Google Scholar
• Mateu‐Puchades A, Santos‐Alarcón S, Martorell‐Calatayud A, et al. Erythrodermic psoriasis and secukinumab: Our clinical experience. Dermatol Ther. 2018;31(4):e12607.
   PubMed Web of Science ®Google Scholar
• Mugheddu C, Atzori L, Lappi A, et al. Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2017;31(9):e420–421.
   PubMed Web of Science ®Google Scholar
• Pescitelli L, Dini V, Gisondi P, et al. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis. J Dermatol Sci. 2015;78(2):149–151.
   PubMed Web of Science ®Google Scholar
• Poulalhon N, Begon E, Lebbe C, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007;156(2):329–336.
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29(6):1148–1155.
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (UNCOVER‐J). J Dermatol. 2017;44(4):355–362.
   PubMed Web of Science ®Google Scholar
• Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin‐23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52‐week, phase 3, multicenter, open‐label study. J Dermatol. 2018;45(5):529–539.
   PubMed Web of Science ®Google Scholar
• Santos-Juanes J, Coto-Segura P, Mas-Vidal A, et al. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Br J Dermatol. 2010;162(5):1144–1146.
   PubMed Web of Science ®Google Scholar
• Viguier M, Pagès C, Aubin F, et al. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol. 2012;167(2):417–423.
   PubMed Web of Science ®Google Scholar
• Wang T-S, Tsai T-F. Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: a case series. J Dermatol. 2011;38(11):1096–1099.
   PubMed Web of Science ®Google Scholar
• Weng H‐J, Wang T‐S, Tsai T‐F. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series. Br J Dermatol. 2018;178(6):1439–1440.
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Nakagawa H, Kubo Y, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52‐week, open‐label study. Br J Dermatol. 2017;176(3):741–751.
   PubMed Web of Science ®Google Scholar
• Kharaeva Z, Gostova E, De Luca C, et al. Clinical and biochemical effects of coenzyme Q10, vitamin E, and selenium supplementation to psoriasis patients. Nutrition. 2009;25(3):295–302.
   PubMed Web of Science ®Google Scholar
• Moy AP, Murali M, Kroshinsky D, et al. Immunologic overlap of helper T-cell subtypes 17 and 22 in erythrodermic psoriasis and atopic dermatitis. JAMA Dermatol. 2015;151(7):753–760.
   PubMed Web of Science ®Google Scholar
• Cole D, Mohammad T, Lim H. Rapid response of pityriasis rubra pilaris with psoriasis overlap to secukinumab [published online ahead of print July 1, 2019]. Br J Dermatol.
   Google Scholar
• National Center for Biotechnology Information. US National Library of Medicine. PubChem. Etretinate; (cited 2019 Aug 18). Available from https://pubchem.ncbi.nlm.nih.gov/compound/Etretinate.
   Google Scholar